Sanofi Quarterly Cash Flow Statements Chart
Quarterly
|
Annual
Sanofi Quarterly Cash Flow Statements Table
Quarterly
|
Annual
| Unit: USD | |
|---|---|
| net income attributable to equity holders of sanofi | |
| non-controlling interests | |
| share of undistributed earnings from investments accounted for using the equity method | |
| depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets | |
| gains and losses on disposals of non-current assets, net of tax | |
| net change in deferred taxes | |
| net change in non-current provisions and other non-current liabilities | |
| cost of employee benefits | |
| impact of the workdown of acquired inventories remeasured at fair value | |
| other profit or loss items with no cash effect on cash flows generated by operating activities | |
| operating cash flow before changes in working capital | |
| (increase)/decrease in inventories | |
| (increase)/decrease in accounts receivable | |
| increase/(decrease) in accounts payable | |
| net change in other current assets and other current liabilities | |
| net cash provided by/ | |
| acquisitions of property, plant and equipment and intangible assets | |
| acquisitions of consolidated undertakings and investments accounted for using the equity method | |
| acquisitions of other equity investments | |
| proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax | |
| disposal of consolidated undertakings and investments accounted for using the equity method, net of tax | |
| net change in other non-current assets | |
| net cash provided by/(used in) investing activities | |
| issuance of sanofi shares | |
| dividends paid: | |
| •to shareholders of sanofi | |
| •to non-controlling interests | |
| payments received/(made) on changes of ownership interest in a subsidiary without loss of control | |
| additional long-term debt contracted | |
| repayments of long-term debt | |
| repayments of lease liabilities | |
| net change in short-term debt and other financial instruments | |
| acquisitions of treasury shares | |
| net cash provided by/(used in) financing activities | |
| impact of exchange rates on cash and cash equivalents | |
| net change in cash and cash equivalents | |
| cash and cash equivalents, beginning of period | |
| cash and cash equivalents, end of period | |
| f-8 | |
| gain on regeneron investment arising from transaction of may 29, 2020, net of tax | |
| net proceeds from sale of regeneron shares on may 29, 2020 | |
| net (income)/loss of the exchanged/held-for-exchange animal health business | |
| operating cash flow before changes in working capital and excluding the exchanged/held-for-exchange animal health business | |
| net cash provided by/(used in) investing activities excluding the exchanged/held-for-exchange animal health business | |
| net cash inflow from the exchange of the animal health business for bi’s consumer healthcare business | |
| net cash provided by/(used in) financing activities excluding the exchanged/held-for-exchange animal health business | |
| sanofi form 20-f 2021 | |
| non-controlling interests, excluding bms | |
| other profit or loss items with no cash effect | |
| •to non-controlling interests, excluding bms | |
| net change in short-term debt | |
| sanofi form 20-f 2020 | | |
| share of undistributed earnings of associates and joint ventures | |
| depreciation, amortization and impairment of property, plant and equipment and intangible assets | |
| net change in provisions | |
| unrealized (gains)/losses recognized in income | |
| net change in other current assets, current financial assets and other current liabilities | |
| net cash provided by/(used in) operating activities | |
| acquisitions of investments in consolidated undertakings, net of cash acquired | |
| acquisitions of available-for-sale financial assets | |
| net change in loans and other financial assets | |
| • to shareholders of sanofi | |
| • to non-controlling interests, excluding bms | |
| transactions with non-controlling interests, other than dividends | |
| acquisition of treasury shares | |
| disposals of treasury shares, net of tax | |
| impact of merial cash and cash equivalents | |
| further to the announcement that merial and intervet/schering-plough are to be maintained as separate businesses operating independently, the line items in the statement of cash flows for the comparative periods (2010 and 2009) include cash flows generated by the operating investing and financing activities of merial. the cash and cash equivalents of merial were reported in the balance sheet in assets held for sale or exchange as of december 31, 2009 and 2010. | |
| – net change in cash and cash equivalents excluding merial | |
| – net change in cash and cash equivalents of merial | |
| – net change in cash and cash equivalents including merial | |
| see note c.1. including available-for-sale financial assets. including: | |
| – income tax paid | |
| – interest paid | |
| – interest received | |
| – dividends received from non-consolidated entities | |
| property, plant and equipment, intangible assets, investments in consolidated entities and other non-current financial assets. | |
| net income attributable to equity holders of sanofi-aventis | |
| net income from the held-for-exchange merial business | |
| dividends received from merial | |
| net change in loans and other non-current financial assets | |
| issuance of sanofi-aventis shares | |
| • to shareholders of sanofi-aventis | |
| income tax paid | |
| interest paid | |
| interest received | |
| dividends received from non-consolidated entities | |
| property, plant and equipment, intangible assets, investments in consolidated undertakings and other non-current financial assets. | |
| net income attributable to equity holders of the company | |
| minority interests, excluding bms | |
| share of undistributed earnings of associates | |
| net change in other current assets, financial assets (current) and other current liabilities | |
| • to sanofi-aventis shareholders | |
| • to minority shareholders, excluding bms | |
| additional long-term borrowings | |
| repayments of long-term borrowings | |
| net change in short-term borrowings | |
| see note c.1. | |
| impact of workdown of aventis inventories remeasured at fair value, net of tax | |
| unrealized gains and losses recognized in income | |
| increase/(decrease) in accounts payable and accrued expenses | |
| net change in other current assets, financial assets — current and other current liabilities | |
| net cash from operating activities | |
| net cash from investing activities | |
| net change in other current assets, financial assets – current and other current liabilities | |
| net income | |
| minority interests other than bms | |
| share of earnings of associates, net of dividend and equivalents received | |
| depreciation and amortization | |
| gains and losses on disposals of non-current assets | |
| unrealized gains and losses recognized in income statement | |
| net change in other current assets, financial assets (current) & other current liabilities | |
| acquisitions of property, plant & equipment and intangibles | |
| acquisition of aventis, net of cash acquired | |
| proceeds from disposals of property, plant and equipment, intangibles and other non-current assets | |
| • to minority shareholders other than bms | |
| acquisitions and disposals of treasury shares | |
| minority interests | |
| share in undistributed earnings of equity investees | |
| gains on disposals of fixed assets, net of income taxes | |
| provisions, long-term deferred taxes and other | |
| expensing of research and development and impact of remeasurement of inventories, net of income taxes | |
| dividends received from equity investees | |
| change in other operating assets and liabilities | |
| other acquisitions of investments | |
| proceeds from disposals of fixed assets, net of income taxes | |
| net change in loans, long-term advances and other investing cash flows | |
| capital contribution from minority shareholders | |
| - to sanofi-aventis shareholders | |
| - to minority shareholders of subsidiaries | |
| acquisitions of treasury shares net of disposals, including disposals made in connection with stock options | |
| net cash from financing activities | |
| acquisitions of investments | |
| issuance of sanofi-synthélabo shares | |
| – to sanofi-synthélabo shareholders | |
| – to minority shareholders of subsidiaries | |
| acquisitions of treasury shares net of disposals, including disposals made in connection with stock option plans | |
| changes in working capital | |
| total investments | |
| asset disposals and other items | |
| change in borrowings and other items | |
| dividends paid | |
| repurchase of own shares | |
| – dividends received from equity investees | |
| – (increase)/decrease in inventories | |
| – (increase)/decrease in accounts receivable | |
| – increase/(decrease) in accounts payable | |
| – change in other operating assets and liabilities |
We provide you with 20 years of cash flow statements for Sanofi stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Sanofi stock. Explore the full financial landscape of Sanofi stock with our expertly curated income statements.
The information provided in this report about Sanofi stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.